Business Context and Reporting Period
Company: First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX)
Reporting Period: Quarterly period ended June 30, 2026 (Six months ended June 30, 2026)
Business Overview: A clinical-stage biotechnology company focused on antibody therapies for autoimmune and inflammatory diseases. Key pipeline assets include ANB033 (CD122 antagonist), rosnilimab (pathogenic T cell depleter), and ANB101 (BDCA2 modulator).
Corporate Event: The company completed a spin-off from its former parent, AnaptysBio, Inc., on April 20, 2026. Financial statements for periods prior to the spin-off are presented on a carve-out basis, while post-spin-off results reflect standalone operations.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
Three Months Ended June 30, 2026 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(83,858) | $(89,641) | $(33,374) |
| Operating Expenses | $87,748 | $97,178 | $34,937 |
| Research & Development (R&D) | $59,599 | $80,737 | $25,644 |
| General & Administrative (G&A) | $28,149 | $16,441 | $9,293 |
| Cash and Cash Equivalents (End of Period) | $168,018 | $44,298 | N/A |
| Short-term Investments | $0 | $73,442 | N/A |
| Net Cash Used in Operating Activities | $(64,479) | $(83,643) | N/A |
| Net Cash Provided by Investing Activities | $34,958 | $51,250 | N/A |
| Net Cash Used in Financing Activities | $(40,657) | $(46,389) | N/A |
Note: The company has no operating revenue. Interest income for the six months ended June 30, 2026, was $3.9 million.
Material Changes vs. Prior Period
- Spin-Off Impact: The most significant change is the separation from AnaptysBio on April 20, 2026. The balance sheet as of June 30, 2026, reflects standalone assets and liabilities, whereas the December 31, 2025, balance sheet included allocated amounts from the parent company.
- Liquidity Position: Cash and cash equivalents decreased from $238.2 million (Dec 31, 2025) to $168.0 million (June 30, 2026). Short-term investments were fully liquidated or matured, dropping from $73.4 million to $0.
- Expense Reduction: Total operating expenses decreased by approximately $9.4 million ($97.2M to $87.7M) for the six-month period compared to the prior year. This was driven primarily by a $20.1 million decrease in external R&D costs, offset by a $11.7 million increase in G&A expenses due to personnel costs, stock compensation, and legal fees associated with the spin-off.
- Capital Raise: In connection with the spin-off, the company completed a private placement, issuing approximately 5.8 million shares and receiving gross proceeds of approximately $80 million.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash, cash equivalents, and investments will fund operations for at least the next 12 months from the issuance of the financial statements. No specific revenue or earnings guidance was provided.
- Development Pipeline:
- ANB033: Phase 1b trials ongoing for celiac disease and eosinophilic esophagitis. FDA Fast Track designation granted for celiac disease.
- Rosnilimab: Phase 2b trial in rheumatoid arthritis met primary and secondary endpoints. End-of-Phase 2 meeting with FDA completed in Q1 2026.
- ANB101: Phase 1 trial in healthy volunteers completed in August 2026.
- Risks and Contingencies:
- Capital Needs: The company expects to incur significant operating losses for the foreseeable future and will require additional financing to complete development and commercialization.
- Spin-Off Transition: Risks related to operating as a standalone entity, including the loss of shared services and potential conflicts of interest with AnaptysBio.
- Regulatory and Clinical: Standard biotech risks regarding clinical trial failure, regulatory approval delays, and manufacturing dependencies on third parties.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $168 million cash balance against the projected burn rate, given the expectation of continued losses and no revenue.
- Rosnilimab Phase 3 Path: Confirm the specific requirements and timeline for Phase 3 trials following the successful Phase 2b results and the End-of-Phase 2 FDA meeting.
- Spin-Off Agreements: Review the Separation and Distribution Agreement and Transition Services Agreement with AnaptysBio to understand ongoing cost allocations, indemnification obligations, and potential conflicts of interest.
- Stock-Based Compensation: Monitor the impact of the new 2026 Equity Incentive Plan and the repricing of awards post-spin-off on future operating expenses.
- Private Placement Dilution: Assess the impact of the 5.8 million shares issued in the private placement on existing shareholder ownership percentages.